Location: Solmed Polyclinic (Zagreb)
Study Drug: Experimental drug is an oral, potent, reversible, selective inhibitor of tyrosine kinase 2 (TYK2).
Main Inclusion Criteria: Adult patients who, with or after one line of treatment with any drug for dermatomyositis, have symptoms of the disease, and in whom, within the last two years, investigations have been conducted to exclude the presence of malignant disease.
Status: Enrolling new patients
Start of Patient Enrollment: October 2023
End of patient enrollment: April 2025
